Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin

Oncology Reports

Volumn 23, Issue 1, 2010, Pages 171-175

  Gazzerro, Patrizia ^a   Malfitano, Anna M ^a   Proto, Maria Chiara ^a   Santoro, Antonietta ^a   Pisanti, Simona ^a   Caruso, Maria Gabriella ^b   Notarnicola, Maria ^b   Messa, Caterina ^b   Laezza, Chiara ^c   Misso, Gabriella ^d   Caraglia, Michele ^d   Bifulco, Maurizio ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^c Istituto di Endocrinologia e Oncologia Sperimentale del CNR   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cannabinoid receptor; Colon; Combinatory analysis; Oxaliplatin; Rimonabant

Indexed keywords

CANNABINOID 1 RECEPTOR; OXALIPLATIN; RIMONABANT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; ORGANOPLATINUM COMPOUNDS; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; TIME FACTORS;

EID: 76049105445     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000619     Document Type: Article

References (25)

1. Rinaldi-Carmona M, Barth F, Heaulme M, et al: SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350: 240-244, 1994.
2. Rinaldi-Carmona M, Barth F, Héaulme M, et al: Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 56: 1941-1947, 1995.
3. Colombo G, Agabio R, Diaz G, et al: Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63: PL113-PL117, 1998.
4. Simiand J, Keane M, Keane PE, et al: SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 9: 179-181, 1998.
5. Ravinet Trillou C, Arnone M, Delgorge C, et al: Anti-obesity effect of SR 141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284: R345-R353, 2003.
6. Carai MA, Colombo G and Gessa GL: Rimonabant: the first therapeutically relevant cannabinoid antagonist. Life Sci 77: 2339-2350, 2005.
7. Jbilo O, Ravinet-Trillou C, Arnone M, et al: The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 19: 1567-1569, 2005.
8. Bifulco M, Grimaldi C, Gazzerro P, et al: Rimonabant: just an anti-obesity drug? Current evidence on its pleiotropic effects. Mol Pharmacol 71: 1445-1456, 2007.
9. Teixeira-Clerc F, Julien B, Grenard P, et al: CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 12: 671-676, 2006.
10. Croci T, Landi M, Galzin AM, et al: Role of cannabinoid CB1 receptors and tumor necrosis factor-a in the gut and systemic anti-inflammatory activity of SR141716 (Rimonabant) in rodents. Br J Pharmacol 140: 115-122, 2003.
11. Di Marzo V and Matias I: Endocannabinoid control of food intake and energy balance. Nat Neurosci 8: 585-589, 2005.
12. Engeli S, Bohnke J, Feldpausch M, et al: Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54: 2838-2843, 2005.
13. Matias I, Gonthier MP, Orlando P, et al: Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91: 3171-3180, 2006.
14. Grimaldi C, Pisanti S, Laezza C, et al: Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res 312: 363-373, 2006.
15. Bifulco M, Laezza C, Valenti M, et al: A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J 18: 1606-1608, 2004.
16. Bouaboula M, Rinaldi M, Carayon O, et al: Cannabinoid-receptor expression in human leukocytes. Eur J Biochem 214: 173-180, 1993.
17. Hurst DP, Lynch DL, Barnett-Norris J, et al: N-(piperidin-1-yl)-5- (4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1Hpyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol Pharmacol 62: 1274-1287, 2002.
18. Sarnataro D, Pisanti S, Santoro A, et al: The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol Pharmacol 70: 1298-1306, 2006.
19. Troiani T, Lockerbie O, Morrow M, et al: Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. Mol Cancer Ther 5: 1883-1894, 2006.
20. Voigt W, Pickan V, Pfeiffer C, et al: Preclinical evaluation of ZD1839 alone or in combination with oxaliplatin in a panel of human tumor cell lines - implications for clinical use. Onkologie 28: 482-488, 2005.
21. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
22. Takahashi N, LiW, Banerjee D, et al: Sequence dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res 62: 6909-6915, 2002.
23. Bifulco M, Laezza C, Portella G, et al: Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J 15: 2745-2747, 2001.
24. Flygare J, Gustafsson K, Kimby E, et al: Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS Lett 579: 6885-6889, 2005.
25. Santoro A, Pisanti S, Grimaldi C, Izzo AA, Borrelli F, Proto MC, Malfitano AM, Gazzerro P, Laezza C, Bifulco M: Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon. Int J Cancer 125: 996-1003, 2009.